TGFB1 and neoplasm: 975A2 MDOTS were treated with the selected immunomodulatory drugs in combination with anti-TGFβ and/or anti-PD-1 antibodies, and then co-cultured with splenocytes from tumor-bearing mice, both in ULA plates and microfluidic devices to study the effect on the functional status of CD8+ T cells and NK cells and the dynamic interactions between immune and tumor cells [44], respectively (Fig. 4 and Supplementary Fig. S5).